Engineered immune cells take aim at Hard-to-Treat blood cancer

NCT ID NCT07185490

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized treatment called IASO104 for people with relapsed or refractory multiple myeloma, a blood cancer that has not responded to standard therapies. IASO104 is made from a patient's own immune cells, which are genetically modified to recognize and attack cancer cells. The study will enroll 40 participants to evaluate safety, find the best dose, and get an early look at whether the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IASO104 (a personalized CAR-T cell therapy targeting BCMA)
What this could lead to: If successful, this could point toward a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early, small trial (40 people) focused on safety and dosing. It may not show strong effectiveness, and CAR-T therapies carry risks like severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL LEUKEMIA (PCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell leukemia plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL LEUKEMIA (PCL) RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

More trials for these conditions

Other studies related to the condition(s) this trial covers.